# BHV-1530

Source: https://onco.cc/drugs/bhv-1530/  
OnCo record `bhv-1530` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BHV-1530 is an experimental antibody-drug conjugate from Biohaven, in phase 1 trials for urothelial cancer and other solid tumours.

## Summary

BHV-1530 is an antibody-drug conjugate from Biohaven. An antibody-drug conjugate directed at FGFR3. Biohaven's pipeline lists it in phase 1b for urothelial cancer and other tumours; the phase 1 study NCT06874335 tests it alone and with cemiplimab. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: AMB302
- Tags: pipeline; ctgov-ingest
- Code: BHV-1530
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate directed at FGFR3.

## Sources

- Biohaven pipeline: https://www.biohaven.com/pipeline/
- ClinicalTrials.gov NCT06874335: https://clinicaltrials.gov/study/NCT06874335

## Connected records

- targets: [FGFR3](https://onco.cc/targets/fgfr3-receptor/)
- companies: [Biohaven](https://onco.cc/companies/biohaven/)
- trials: [A Phase 1 Study of BHV-1530 in Advanced Solid Tumors](https://onco.cc/trials/nct06874335/)

---
JSON: https://onco.cc/api/v1/entities/bhv-1530.json